P. Bombaron

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Ali Chour, Julie Denis, Céline Mascaux et al. · Journal of Thoracic Oncology · 2023 · 72 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study

Alexis B. Cortot, L. Gérinière, G. Robinet et al. · Annals of Oncology · 2006 · 47 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Fabrice Barlési, A. Dixmier, D. Debieuvre et al. · OncoImmunology · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Teresa Morán, Jia Wei, Manuel Cobo et al. · Annals of Oncology · 2014 · 30 citations · Full text

Medicine, Cancer Biology, Oncology +17